Spinal and peripheral mechanisms of cannabinoid antinociception: Behavioral, neurophysiological and neuroanatomical perspectives

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 173-190

  Hohmann, Andrea G ^a  

^a University of Georgia ^*  (United States)

Author keywords

Anandamide; Dorsal horn; Dorsal root ganglia; Endocannabinoid; Pain; Spinal cord

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANALGESIC AGENT; ANANDAMIDE; ANTINOCICEPTIVE AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; DEXANABINOL; DRONABINOL; METHYSERGIDE; PALMIDROL; RECEPTOR SUBTYPE; RIMONABANT; YOHIMBINE;

ANTINOCICEPTION; BEHAVIOR; CONFERENCE PAPER; DRUG EFFICACY; DRUG RECEPTOR BINDING; IMMUNOREACTIVITY; INFLAMMATION; MUSCLE SPINDLE AFFERENT NERVE; NERVE FIBER TRANSPORT; NEUROANATOMY; NEUROPATHIC PAIN; NEUROPHYSIOLOGY; NOCICEPTION; NONHUMAN; PAIN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSATION; SPINAL CORD; SPINAL GANGLION; VISCERAL PAIN;

ANIMALS; BIOLOGICAL TRANSPORT; CANNABINOIDS; CYTOLOGICAL TECHNIQUES; NOCICEPTORS; PAIN; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; SPINAL CORD; SYNAPTIC TRANSMISSION;

ANIMALIA;

EID: 0037207078     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00154-8     Document Type: Conference Paper

References (130)

1. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
2. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid 1 receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
3. Ahluwalia J., Urban L., Bevan S., Capogna M., Nagy I. Cannabinoid 1 receptors are expressed by nerve growth factor- and glial cell-derived neurotrophic factor-responsive primary sensory neurones. Neuroscience. 110:2002;747-753.
4. Arner S., Meyerson B.A. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain. 33:1988;11-23.
5. Averill S., McMahon S.B., Clary D.O., Reichardt L.F., Priestley J.V. Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. Eur. J. Neurosci. 7:1995;1484-1494.
6. Beaulieu P., Bisogno T., Punwar S., Farquhar-Smith W.P., Ambrosino G., Di Marzo V., Rice A.S. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur. J. Pharmacol. 396:2000;85-92.
7. Bennett D.L., Averill S., Clary D.O., Priestley J.V., McMahon S.B. Postnatal changes in the expression of the trkA high-affinity NGF receptor in primary sensory neurons. Eur. J. Neurosci. 8:1996;2204-2208.
8. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 353:1998;23-31.
9. Besse D., Lombard M.C., Zajac J.M., Roques B.P., Besson J.M. Pre- and postsynaptic distribution of μ, δ and κ opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord. Brain Res. 521:1990;15-22.
10. Bloom A.S., Dewey W.L., Harris L.S., Brosius K.K. 9-nor-9beta-Hydroxyhexahydrocannabinol, a cannabinoid with potent antinociceptive activity: comparisons with morphine. J. Pharmacol. Exp. Ther. 200:1977;263-270.
11. Bridges D., Ahmad K., Rice A.S. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol. 133:2001;586-594.
12. Bridges D., Rice A.S.C., Egertova M., Elphick M.R., Winter J. The cannabinoid CB1 receptor is localised predominantly on N52 within the rat dorsal root ganglion. Soc. Neurosci. Abst. 27:2001;713-716.
13. Buckley N.E., McCoy K.L., Mezey E., Bonner T., Zimmer A., Felder C.C., Glass M. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol. 396:2000;141-149.
14. 9-tetrahydrocannabinol in the rat and mouse. Psychopharmacologia. 25:1972;275-280.
15. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
16. Calza L., Pozza M., Zanni M., Manzini C.U., Manzini E., Hokfelt T. Peptide plasticity in primary sensory neurons and spinal cord during adjuvant-induced arthritis in the rat: an immunocytochemical and in situ hybridization study. Neuroscience. 82:1998;575-589.
17. Caulfield M.P., Brown D.A. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br. J. Pharmacol. 106:1992;231-232.
18. Chapman V. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat. Br. J. Pharmacol. 127:1999;1765-1767.
19. Chapman V. Functional changes in the inhibitory effect of spinal cannabinoid (CB) receptor activation in nerve injured rats. Neuropharmacology. 41:2001;870-877.
20. Chung K., Langford L.A., Coggeshall R.E. Primary afferent and propriospinal fibers in the rat dorsal and dorsolateral funiculi. J. Comp. Neurol. 263:1987;68-75.
21. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature. 384:1996;83-87.
22. Deadwyler S.A., Hampson R.E., Mu J., Whyte A., Childers S. Cannabinoids modulate voltage-sensitive potassium A - current in hippocampal neurons via a cAMP-dependent process. J. Pharmacol. Exp. Ther. 273:1995;734-743.
23. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
24. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
25. Donaldson L.F., McQueen D.S., Seckl J.R. Local anaesthesia prevents acute inflammatory changes in neuropeptide messenger RNA expression in rat dorsal root ganglia neurons. Neurosci. Lett. 175:1994;111-113.
26. 35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats. Eur. J. Neurosci. 12:2000;2079-2086.
27. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S.D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
28. Farquhar-Smith W.P., Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 94:2001;507-513. (Discussion 506A).
29. Farquhar-Smith W.P., Egertova M., Bradbury E.J., McMahon S.B., Rice A.S., Elphick M.R. Cannabinoid CB(1) receptor expression in rat spinal cord. Mol. Cell. Neurosci. 15:2000;510-521.
30. Farquhar-Smith W.P., Jaggar S.I., Rice A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain. 97:2002;11-21.
31. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450.
32. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral Cannabinoid 1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100.
33. Galeazza M.T., Garry M.G., Yost H.J., Strait K.A., Hargreaves K.M., Seybold V.S. Plasticity in the synthesis and storage of substance P and calcitonin gene-related peptide in primary afferent neurons during peripheral inflammation. Neuroscience. 66:1995;443-458.
34. Gauldie S.D., McQueen D.S., Pertwee R., Chessell I.P. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol. 132:2001;617-621.
35. Gerard C.M., Mollereau C., Vassart G., Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279:1991;129-134.
36. Gilbert P.E. A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J. Clin. Pharmacol. 21:1981;311S-319S.
37. Gong L.W., Ding Y.Q., Wang D., Zheng H.X., Qin B.Z., Li J.S., Kaneko T., Mizuno N. GABAergic synapses on mu-opioid receptor-expressing neurons in the superficial dorsal horn: an electron microscope study in the cat spinal cord. Neurosci. Lett. 227:1997;33-36.
38. Grant G. Primary afferent projections to the spinal cord. Paxinos G. The Rat Nervous System. 2nd Ed. 1995;61-65 Academic Press, New York.
39. Hanesch U., Blecher F., Stiller R.U., Emson P.C., Schaible H.G., Heppelmann B. The effect of a unilateral inflammation at the rat's ankle joint on the expression of preprotachykinin-A mRNA and preprosomatostatin mRNA in dorsal root ganglion cells- - a study using non-radioactive in situ hybridization. Brain Res. 700:1995;279-284.
40. Hanus L., Breuer A., Tchilibon S., Shiloah S., Goldenberg D., Horowitz M., Pertwee R.G., Ross R.A., Mechoulam R., Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc. Natl. Acad. Sci. USA. 96:1999;14228-14233.
41. Harris J., Drew L.J., Chapman V. Spinal anandamide inhibits nociceptive transmission via cannabinoid receptor activation in vivo. Neuroreport. 11:2000;2817-2819.
42. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11:1991;563-583.
43. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221:1997;157-160.
44. Hohmann A.G., Herkenham M. Localization of cannabinoid receptor (CB1) mRNA in neuronal subpopulations of rat spinal cord and dorsal root ganglia. Soc. Neurosci. Abst. 23:1997;760-763.
45. Hohmann A.G., Herkenham M. Regulation of cannabinoid and mu opioid receptor binding sites following neonatal capsaicin treatment. Neurosci. Lett. 252:1998;13-16.
46. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
47. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90:1999;923-931.
48. Hohmann A.G., Herkenham M. Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse. 37:2000;71-80.
49. Hohmann A.G., Martin W.J., Tsou K., Walker J.M. Inhibition of noxious stimulus-evoked activity of spinal cord dorsal horn neurons by the cannabinoid WIN 55,212-2. Life Sci. 56:1995;2111-2118.
50. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid modulation of wide dynamic range neurons in the lumbar dorsal horn of the rat by spinally administered WIN55,212-2. Neurosci. Lett. 257:1998;119-122.
51. Hohmann A.G., Briley E.M., Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res. 822:1999;17-25.
52. Hohmann A.G., Tsou K., Walker J.M. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J. Neurophysiol. 81:1999;575-583.
53. Hohmann A.G., Tsou K., Walker J.M. Intrathecal cannabinoid administration suppresses noxious-stimulus evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Acta Pharmacol. Sinica. 20:1999;1132-1136.
54. Hohmann A.G., Neely M.H., Suplita R.L., Nackley A.G., Holmes P.V., Crystal J.D. Endocannabinoid mechanisms of stress-induced analgesia. Soc. Neurosci. Abst. 27:2001;716-719.
55. Howlett A.C., Qualy J.M., Khachatrian L.L. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol. Pharmacol. 29:1986;307-313.
56. Hunt S.P., Pini A., Evan G. Induction of c-fos-like protein in spinal cord neurons following sensory stimulation. Nature. 328:1987;632-634.
57. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
58. Jaggar S.I., Sellaturay S., Rice A.S. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci. Lett. 253:1998;123-126.
59. Jennings E.A., Vaughan C.W., Christie M.J. Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro. J. Physiol. 534:2001;805-812.
60. Ji R.R., Zhang X., Wiesenfeld-Hallin Z., Hokfelt T. Expression of neuropeptide Y and neuropeptide Y (Y1) receptor mRNA in rat spinal cord and dorsal root ganglia following peripheral tissue inflammation. J. Neurosci. 14:1994;6423-6434.
61. Ji R.R., Zhang X., Zhang Q., Dagerlind A., Nilsson S., Wiesenfeld-Hallin Z., Hokfelt T. Central and peripheral expression of galanin in response to inflammation. Neuroscience. 68:1995;563-576.
62. Johanek L.M., Heitmiller D.R., Turner M., Nader N., Hodges J., Simone D.A. Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain. 93:2001;303-315.
63. Kelly S., Chapman V. Selective cannabinoid CB1 receptor activation inhibits spinal nociceptive transmission in vivo. J. Neurophysiol. 86:2001;3061-3064.
64. Kemp T., Spike R.C., Watt C., Todd A.J. The mu-opioid receptor (MOR1) is mainly restricted to neurons that do not contain GABA or glycine in the superficial dorsal horn of the rat spinal cord. Neuroscience. 75:1996;1231-1238.
65. 9-tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: a peripheral cannabinoid action. Psychopharmacology (Berlin). 143:1999;322-326.
66. Kosersky D.S., Dewey W.L., Harris L.S. Antipyretic, analgesic and anti-inflammatory effects of delta 9-tetrahydrocannabinol in the rat. Eur. J. Pharmacol. 24:1973;1-7.
67. Lambert D.M., DiPaolo F.G., Sonveaux P., Kanyonyo M., Govaerts S.J., Hermans E., Bueb J., Delzenne N.M., Tschirhart E.J. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. Biochim. Biophys. Acta. 1440:1999;266-274.
68. Landsman R.S., Burkey T.H., Consroe P., Roeske W.R., Yamamura H.I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
69. Leslie T.A., Emson P.C., Dowd P.M., Woolf C.J. Nerve growth factor contributes to the up-regulation of growth-associated protein 43 and preprotachykinin A messenger RNAs in primary sensory neurons following peripheral inflammation. Neuroscience. 67:1995;753-761.
70. Levine J.D., Reichling D.B. Peripheral mechanisms of inflammatory pain. Wall P.D., Melzack R. Textbook of Pain. 1999;59-84 Churchill Livingstone, London.
71. Li J., Daughters R.S., Bullis C., Bengiamin R., Stucky M.W., Brennan J., Simone D.A. The cannabinoid receptor agonist WIN 55,212-2 mesylate blocks the development of hyperalgesia produced by capsaicin in rats. Pain. 81:1999;25-33.
72. 2-noradrenergic mechanism. Brain Res. 559:1991;309-314.
73. Lichtman A.H., Martin B.R. Spinal and supraspinal components of cannabinoid-induced antinociception. J. Pharmacol. Exp. Ther. 258:1991;517-523.
74. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1994;1612-1623.
75. Mackie K., Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. USA. 89:1992;3825-3829.
76. Mackie K., Lai Y., Westenbroek R., Mitchell R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci. 15:1995;6552-6561.
77. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
78. Malan T.P. Jr., Ibrahim M.M., Deng H., Liu Q., Mata H.P., Vanderah T., Porreca F., Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain. 93:2001;239-245.
79. Malan T.P. Jr., Ibrahim M.M., Vanderah T.W., Makriyannis A., Porreca F. Inhibition of pain responses by activation of CB2 cannabinoid receptors. Chem. Phys. Lipids. 121:2002;191-200.
80. Malmberg A.B., Chen C., Tonegawa S., Basbaum A.I. Preserved acute pain and reduced neuropathic pain in mice lacking PKCgamma. Science. 278:1997;279-283.
81. Mao J., Price D.D., Lu J., Keniston L., Mayer D.J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci. Lett. 280:2000;13-16.
82. Martin B.R., Compton D.R., Thomas B.F., Prescott W.R., Little P.J., Razdan R.K., Johnson M.R., Melvin L.S., Mechoulam R., Ward S.J. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol. Biochem. Behav. 40:1991;471-478.
83. Martin W.J., Hohmann A.G., Walker J.M. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J. Neurosci. 16:1996;6601-6611.
84. Martin W.J., Loo C.M., Basbaum A.I. Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. Pain. 82:1999;199-205.
85. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
86. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur. J. Pharmacol. 300:1996;227-236.
87. McMahon S.B., Bennett D.L. Trophic factors and pain. Wall P.D., Melzack R. Textbook of Pain. 1999;105-129 Churchill Livingstone, London.
88. Meng I.D., Manning B.H., Martin W.J., Fields H.L. An analgesia circuit activated by cannabinoids. Nature. 395:1998;381-384.
89. Michael G.J., Averill S., Nitkunan A., Rattray M., Bennett D.L., Yan Q., Priestley J.V. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci. 17:1997;8476-8490.
90. Miller M.A., Kolb P.E., Raskind M.A. A method for simultaneous detection of multiple mRNAs using digoxigenin and radioisotopic cRNA probes. J. Histochem. Cytochem. 41:1993;1741-1750.
91. Millns P.J., Chapman V., Kendall D.A. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion neurones. Br. J. Pharmacol. 132:2001;969-971.
92. Molander C., Grant G. Spinal cord cytoarchitecture. Paxinos G. The Rat Nervous System. 1995;39-45 Academic Press, San Diego.
93. Molliver D.C., Radeke M.J., Feinstein S.C., Snider W.D. Presence or absence of TrkA protein distinguishes subsets of small sensory neurons with unique cytochemical characteristics and dorsal horn projections. J. Comp. Neurol. 361:1995;404-416.
94. Morisset V., Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J. Neurophysiol. 86:2001;40-48.
95. Morisset V., Ahluwalia J., Nagy I., Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur. J. Pharmacol. 429:2001;93-100.
96. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
97. Nackley, A.G., Suplita II, R.L., Hohmann, A.G., in press. A periperal cannabinoid mechanism suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience.
98. Nagy J.I., Hunt S.P. Fluoride-resistant acid phosphatase-containing neurones in dorsal root ganglia are separate from those containing substance P or somatostatin. Neuroscience. 7:1982;89-97.
99. Nagy J.I., Vincent S.R., Staines W.A., Fibiger H.C., Reisine T.D., Yamamura H.I. Neurotoxic action of capsaicin on spinal substance P neurons. Brain Res. 186:1980;435-444.
100. Neumann S., Doubell T.P., Leslie T., Woolf C.J. Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature. 384:1996;360-364.
101. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
102. Price T.J., Dussor G.D., Hargreaves K.M., Flores C.M. Expression and distribution of cannabinoid receptor subtypes in trigeminal ganglion: colocalization with nociceptive markers. Soc. Neurosci. Abst. 31:2001;716.13.
103. Rice A.S., Farquhar-Smith W.P., Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins. Leukot. Essent. Fatty. Acids. 66:2002;243-256.
104. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur. J. Pharmacol. 345:1998;145-153.
105. Richardson J.D., Aanonsen L., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
106. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998;111-119.
107. Rinaldi-Carmona M., Barth F., Heaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Neliat G., Caput D., et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
108. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
109. Ross R.A., Coutts A.A., McFarlane S.M., Anavi-Goffer S., Irving A.J., Pertwee R.G., MacEwan D.J., Scott R.H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology. 40:2001;221-232.
110. Salio C., Fischer J., Franzoni M.F., Mackie K., Kaneko T., Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport. 12:2001;3689-3692.
111. Salio C., Doly S., Fischer J., Franzoni M., Conrath M. Neuronal and astrocytic localization of the cannabinoid receptor-1 in the dorsal horn of the rat spinal cord. Neurosci. Lett. 329:2002;13.
112. Salio C., Fischer J., Franzoni M.F., Conrath M. Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. Neuroscience. 110:2002;755-764.
113. Sañudo-Peña M.C., Strangman N.M., Mackie K., Walker J.M., Tsou K. CB1 receptor localization in rat spinal cord and roots, dorsal root ganglion, and peripheral nerve. Acta Pharmacol. Sinica. 20:1999;1115-1120.
114. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Caput D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing [published erratum appears in J. Biol. Chem. 27;271(52):33706]. J. Biol. Chem. 270:1995;3726-3731.
115. Showalter V.M., Compton D.R., Martin B.R., Abood M.E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype-selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
116. Silverman J.D., Kruger L. Selective neuronal glycoconjugate expression in sensory and autonomic ganglia: relation of lectin reactivity to peptide and enzyme markers. J. Neurocytol. 19:1990;789-801.
117. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
118. 9-tetrahydrocannabinol-induced analgesia. Brain Res. 578:1992;8-12.
119. 9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol. Biochem. Behav. 60:1998;183-191.
120. Strangman N.M., Walker J.M. The cannabinoid WIN 55,212-2 inhibits the activity-dependent facilitation of spinal nociceptive responses. J. Neurophys. 81:1999;472-477.
121. Tsou K., Lowitz K.A., Hohmann A.G., Martin W.J., Hathaway C.B., Bereiter D.A., Walker J.M. Suppression of noxious stimulus-evoked expression of FOS protein-like immunoreactivity in rat spinal cord by a selective cannabinoid agonist. Neuroscience. 70:1996;791-798.
122. Tsou K., Brown S., Sanudo-Peña M.C., Mackie K., Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
123. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
124. Walker J.M., Strangman N.M., Huang S.M. Cannabinoids and pain. Pain Res. Manage. 6:2001;74-79.
125. Welch S.P., Thomas C., Patrick G.S. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J. Pharmacol. Exp. Ther. 272:1995;310-321.
126. Willis W.D., Westlund K.N., Carlton S.M. Pain. Paxinos G. The Rat Nervous System. 2nd Ed. 1995;725-750 Academic Press, New York.
127. Yaksh T.L. The antinociceptive effects of intrathecally administered levonantradol and desacetyllevonantradol in the rat. J. Clin. Pharmacol. 21:1981;334S-340S.
128. Young W.S.D., Wamsley J.K., Zarbin M.A., Kuhar M.J. Opioid receptors undergo axonal flow. Science. 210:1980;76-78.
129. Zimmer A., Zimmer A.M., Hohmann A.G., Herkenham M., Bonner T.I. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc. Natl. Acad. Sci. USA. 96:1999;5780-5785.
130. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., Julius D., Hogestatt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.